2013
Translation of Biomedical Prevention Strategies for HIV
Vermund SH, Tique JA, Cassell HM, Pask ME, Ciampa PJ, Audet CM. Translation of Biomedical Prevention Strategies for HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 63: s12-s25. PMID: 23673881, PMCID: PMC3725750, DOI: 10.1097/qai.0b013e31829202a2.Peer-Reviewed Original ResearchConceptsPrevention of motherPrevention strategiesClean injection equipmentChild HIV transmissionBiomedical approachBiomedical prevention strategiesRisk of acquisitionHIV prevention strategiesBehavioral risk reductionHigh-prevalence regionsRisk of transmissionCircumcision of menBlood product safetyChild transmissionHIV transmissionAntiretroviral drugsPrevalence regionsHIV preventionHIVFamily planningMore childrenPreventionRisk reductionInjection equipmentSaharan Africa
2010
Combination HIV Prevention: Significance, Challenges, and Opportunities
Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV Prevention: Significance, Challenges, and Opportunities. Current HIV/AIDS Reports 2010, 8: 62-72. PMID: 20941553, PMCID: PMC3036787, DOI: 10.1007/s11904-010-0063-3.Peer-Reviewed Original ResearchConceptsHIV prevention strategiesHIV transmissionPrevention strategiesPopulation-level HIV transmissionBehavioral risk reductionEvidence-based strategiesNumber of interventionsAntiretroviral medicationsHIV serostatusPrevention packageUninfected personsEpidemiologic profileHIV pandemicMale circumcisionNeedle exchangeEffective interventionsTarget populationInterventionRisk reductionMeasurable reductionPopulation levelDiverse subgroupsMedicationsSerostatusHIV
2000
Network-related Mechanisms May Help Explain Long-term HIV-1 Seroprevalence Levels That Remain High but Do Not Approach Population-Group Saturation
Friedman SR, Kottiri BJ, Neaigus A, Curtis R, Vermund SH, Des Jarlais DC. Network-related Mechanisms May Help Explain Long-term HIV-1 Seroprevalence Levels That Remain High but Do Not Approach Population-Group Saturation. American Journal Of Epidemiology 2000, 152: 913-922. PMID: 11092433, DOI: 10.1093/aje/152.10.913.Peer-Reviewed Original ResearchConceptsDrug injectorsSeroprevalence levelsHIV-1 incidenceHigh-risk subgroupsHuman immunodeficiency virusBehavioral risk reductionHigh prevalence situationsImmunodeficiency virusHigh seroprevalenceSeronegativesPrevention programsRisk behaviorsInfection outbreaksSeroprevalenceInfectious outbreaksMaximum incidenceSecondary outbreaksNetwork-based mechanismsRisk reductionIncidenceOutbreakOutbreak increasesNew York CityPrevalenceYork City